MediWound (MDWD) to Release Quarterly Earnings on Wednesday

MediWound (NASDAQ:MDWD - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.65) per share and revenue of $5.20 million for the quarter.

MediWound (NASDAQ:MDWD - Get Free Report) last issued its quarterly earnings data on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.23. The firm had revenue of $5.84 million during the quarter, compared to analysts' expectations of $5.79 million. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same quarter in the previous year, the company earned ($0.19) earnings per share. On average, analysts expect MediWound to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MediWound Stock Up 0.1%

NASDAQ MDWD traded up $0.03 during trading on Monday, reaching $20.51. 79,756 shares of the stock traded hands, compared to its average volume of 90,874. The firm has a market cap of $221.67 million, a price-to-earnings ratio of -7.07 and a beta of 0.30. The stock's 50-day moving average price is $17.33 and its 200 day moving average price is $17.55. MediWound has a fifty-two week low of $12.78 and a fifty-two week high of $24.00.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. HC Wainwright restated a "buy" rating and set a $25.00 price objective on shares of MediWound in a report on Thursday, March 20th. StockNews.com upgraded shares of MediWound to a "sell" rating in a report on Friday, March 21st. Craig Hallum began coverage on shares of MediWound in a report on Friday, February 28th. They set a "buy" rating and a $39.00 price objective for the company. Finally, Alliance Global Partners began coverage on shares of MediWound in a report on Friday, May 2nd. They issued a "buy" rating and a $25.00 price target for the company. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $29.75.

Institutional Inflows and Outflows

An institutional investor recently raised its position in MediWound stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in MediWound Ltd. (NASDAQ:MDWD - Free Report) by 22.4% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,452 shares of the biopharmaceutical company's stock after buying an additional 999 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.05% of MediWound worth $85,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 46.83% of the company's stock.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.